©2025 Stanford Medicine
18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma
Not Recruiting
Trial ID: NCT04365660
Purpose
The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").
Official Title
A Phase 2 Study of 18F FTC 146 PET/CT in Patients With Newly Diagnosed Osteosarcoma
Stanford Investigator(s)
Kristen N Ganjoo
Professor of Medicine (Oncology)
Eligibility
Inclusion Criteria:
* Patients with biopsy proven osteosarcoma requiring local surgical intervention.
* ECOG ≤ 2
* Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
* Chemotherapy in the past 2 months.
* Prior history of allergic reaction to 18F FTC 146.
* Pregnant or nursing
Intervention(s):
drug: 18-F FTC 146
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Montes
650-725-4185